House
GuidelinesCalculatorsPricingBlog
Ask House ↗
Guidelines↗Calculators↗Pricing↗Blog↗
House
Clinical AIRoundsGuidelinesCalculatorsPricingBlogAboutEditorial policyPrivacyTermsLog in ↗
Clinical intelligence, for physicians.© 2026 House
House
Clinical AIRoundsGuidelinesCalculatorsPricingBlogAboutEditorial policyPrivacyTermsLog in ↗
Clinical intelligence, for physicians.© 2026 House
Back to guidelines
Endocrinology

Diabetes (type 1 and type 2) in children and young people: diagnosis and management

NICE · 2023 edition / updateSource checked 29 October 2026
Read the source publication
House clinical summary

Scope

NICE guideline NG18 covers the diagnosis and management of type 1 and type 2 diabetes in children and young people. Its recommendations cover diagnosis and referral, education, insulin regimens and glucose-lowering medicines, continuous and capillary glucose monitoring, glucose and HbA1c targets, hypoglycaemia, diabetic ketoacidosis (DKA), complication screening, psychosocial care, service provision and transition. Type 2 recommendations dated 2023 set out a stepwise approach using metformin, liraglutide, dulaglutide, empagliflozin and insulin. The summary keeps the source's recommendation strength, so 'offer' is distinct from 'consider' or 'think about'.

Written by House with AI assistance · AI-assisted source check 29 October 2026.

This is House’s summary of the cited guidance. The source check is not an independent clinician review. Open the publication for complete recommendations, exceptions, evidence grades and later amendments.

Diagnosis and referral

  • Hyperglycaemia (random plasma glucose above 11 mmol/litre) is a recognised sign of type 1 diabetes. DKA can be the first presentation and needs urgent diagnosis and management. Refer suspected type 1 diabetes on the same day to a multidisciplinary paediatric diabetes team. Confirm the diagnosis using the plasma glucose criteria in the WHO 2006 report. [1]
  • Assume type 1 diabetes unless there are strong indications of type 2, monogenic or mitochondrial diabetes. Features that should prompt thinking about type 2 diabetes include the following (partial list; the source names further criteria): - a strong family history of type 2 diabetes - a Black or Asian family background - evidence of insulin resistance, such as acanthosis nigricans - no insulin need, or a need below 0.5 units/kg body weight/day after the partial remission phase [1]
  • Do not use C-peptide or diabetes-specific autoantibodies at initial presentation to separate type 1 from type 2 diabetes. C-peptide may be considered later to distinguish type 1 from other types of diabetes. Perform genetic testing when atypical features or family history suggest monogenic diabetes. [1]

Type 1 diabetes: treatment, targets and monitoring

  • Offer a multiple daily injection basal-bolus regimen from diagnosis. Consider an insulin pump if multiple daily injections are not appropriate. Offer level 3 carbohydrate counting education from diagnosis to children and young people using either approach. Do not offer acarbose or sulfonylureas with insulin. Use metformin with insulin only within research studies. [1]
  • Optimal plasma glucose targets are: - fasting on waking and before meals: 4–7 mmol/litre - after meals: 5–9 mmol/litre - when driving: at least 5 mmol/litre [1]
  • Explain that an HbA1c of 48 mmol/mol (6.5%) or lower minimises the risk of long-term complications. Agree an individualised lowest achievable target, taking account of daily activities, life goals, complications, comorbidities and hypoglycaemia risk. Measure HbA1c 4 times a year, and think about more frequent testing if blood glucose management is difficult. [1]
  • Offer real-time CGM with education to all children and young people with type 1 diabetes. Offer isCGM (flash) from age 4 years to those unable to use rtCGM or who clearly prefer isCGM. Capillary testing is still needed, though less often. If the device is worn less than 70% of the time, ask whether they are having problems with it. Then look at ways to address any problems or concerns to improve use, including further education and emotional and psychological support. [1]
  • Give individualised oral and written sick-day advice and revisit it at least annually. Offer blood ketone strips and a meter, with advice to test for ketonaemia during illness or hyperglycaemia. [1]

Hypoglycaemia (type 1 diabetes)

  • Treat mild-to-moderate hypoglycaemia immediately with oral fast-acting glucose, for example 10–20 g. Recheck blood glucose within 15 minutes and give more if hypoglycaemia persists. [1]
  • For severe hypoglycaemia: - In hospital with rapid IV access: give 10% IV glucose, up to a maximum of 500 mg/kg (5 ml/kg). - Outside hospital, or if rapid IV access is not possible: give IM glucagon (1 mg if over 8 years or 25 kg or more; 500 micrograms if under 8 years or less than 25 kg) or concentrated oral glucose solution. - Do not give oral glucose solution if consciousness is reduced. - Seek medical help if there is no response or symptoms last more than 10 minutes. [1]

Type 2 diabetes: treatment and monitoring

  • Refer suspected type 2 diabetes to a multidisciplinary paediatric diabetes team. Offer dietary support, metformin monotherapy in the preferred formulation and capillary monitoring equipment; in May 2023, formulations other than standard-release metformin were off-label. Also offer insulin if HbA1c is 69 mmol/mol (8.5%) or more, and basal-bolus insulin for ketosis without DKA. If DKA features are present, follow the DKA recommendations. [1]
  • Review glucose data four weeks after starting metformin and change treatment if needed. After that, review treatment at least every 3 months. If HbA1c is unreliable because of disturbed erythrocyte turnover or abnormal haemoglobin, estimate glucose trends using one of these: glucose profiles, total glycated haemoglobin estimation (if abnormal haemoglobins) or fructosamine estimation. [1]
  • For those aged 10 or over on metformin, offer add-on liraglutide or dulaglutide (by preference) if any of these apply: - HbA1c above 48 mmol/mol (6.5%) - plasma glucose above 7 mmol/litre fasting or before meals on 4 or more days a week - plasma glucose above 9 mmol/litre 2 hours after meals on 4 or more days a week Consider empagliflozin for those who meet any of these criteria and cannot tolerate liraglutide or dulaglutide or clearly prefer empagliflozin. Dulaglutide use was off-label in May 2023. [1]
  • Offer insulin if an HbA1c of 48 mmol/mol (6.5%) or less is not reached with metformin plus one of liraglutide, dulaglutide or empagliflozin. For those aged 10 or over already on insulin whose levels do not permit insulin withdrawal, offer liraglutide or dulaglutide rather than increasing insulin. For those aged 10 or over on metformin and insulin, increase insulin only if HbA1c or glucose levels are outside the target ranges in recommendation 1.3.48 and one of these agents is already being taken, or all of them are not tolerated or are contraindicated. [1]
  • Offer rtCGM in type 2 diabetes when any of these apply: - a need, condition or disability prevents capillary monitoring - self-monitoring would otherwise be advised at least 8 times a day - hypoglycaemia is recurrent or severe Consider rtCGM for those on insulin therapy. [1]

Diabetic ketoacidosis

  • In a child or young person without known diabetes, suspect DKA if plasma glucose is above 11 mmol/litre with suggestive symptoms, and send them immediately to a hospital with acute paediatric facilities. Be aware that children and young people taking insulin may develop DKA with normal blood glucose levels. In a child or young person with known diabetes, suspect DKA even if blood glucose is normal when features are present, including nausea or vomiting, abdominal pain, hyperventilation or reduced level of consciousness (partial list; the source names a further feature). [1]
  • Diagnose DKA when all 3 are present: - plasma glucose above 11 mmol/litre - acidosis: pH below 7.3 or bicarbonate below 15 mmol/litre - ketones: beta-hydroxybutyrate above 3 mmol/litre, or urine ketones ++ or more Grade severity as moderate if pH is below 7.2 or bicarbonate below 10 mmol/litre, and severe if pH is below 7.1 or bicarbonate below 5 mmol/litre. [1]
  • Initial fluid boluses in DKA: - Clinically dehydrated without shock: give an initial 10 ml/kg 0.9% sodium chloride bolus over 30 minutes, and discuss with the responsible senior paediatrician before giving more than one such bolus. Consider a second 10 ml/kg bolus only if it is needed to improve tissue perfusion, and only after reassessing clinical status. Subtract bolus volumes from the fluid deficit. - Signs of shock (weak, thready pulse and hypotension): give a 10 ml/kg 0.9% sodium chloride bolus as soon as possible, and do not subtract it from the deficit. [1]
  • Calculate the total fluid requirement for the first 48 hours as the estimated deficit plus maintenance. Assume 5% dehydration if pH is 7.1 or above, and 10% if it is below 7.1. Aim to replace the deficit evenly over the first 48 hours. In critically ill children and young people, discuss the fluid regimen early with the senior paediatrician, paediatric intensivist or both, because the risk of cerebral oedema is higher. Calculate maintenance using the Holliday–Segar formula. [1]
  • Start soluble IV insulin 1 to 2 hours after starting IV fluids, at 0.05–0.1 units/kg/hour, and do not give IV insulin boluses. When plasma glucose falls below 14 mmol/litre, switch to 0.9% sodium chloride with 5% glucose and 40 mmol/litre potassium chloride. [1]
  • Add 40 mmol/litre potassium chloride to all fluids except the initial boluses, unless there is anuria or potassium is above the normal range. If potassium is above the normal range, add it only if potassium is less than 5.5 mmol/litre or there is a history of passing urine. If hypokalaemia is present at presentation, add potassium chloride to IV fluids before starting the insulin infusion. [1]
  • Assess immediately for cerebral oedema if early signs such as an unexpected fall in heart rate appear, and start treatment immediately if it is suspected. Use whichever is most readily available: - mannitol 20%, 0.5–1 g/kg over 10–15 minutes - hypertonic sodium chloride 2.7% or 3%, 2.5–5 ml/kg over 10–15 minutes [1]

Complication monitoring

  • In type 1 diabetes, offer thyroid monitoring at diagnosis and then annually until transfer to adult services. From 12 years, offer annual monitoring for albuminuria (ACR 3–30 mg/mmol) and hypertension, and refer for retinopathy screening. Confirm an initial ACR between 3 and 30 mg/mmol with 2 further early-morning samples before starting further investigation and therapy. [1]
  • In type 2 diabetes, offer annual monitoring from diagnosis for hypertension, dyslipidaemia and moderately increased albuminuria (ACR 3–30 mg/mmol). If repeated resting blood pressure exceeds the 95th percentile for age and sex, confirm hypertension with 24-hour ambulatory monitoring before starting antihypertensive treatment. [1]

Limitations and use

  • Covers children and young people only; adult diabetes care is outside the scope.
  • Research recommendations, rationale and update-history chapters were not part of the reviewed clinical source. Linked flowcharts were available as alternative text only.
  • Many recommendations refer to other NICE guidelines (for example, coeliac disease, diabetic foot, eating disorders and depression) and to UK services such as NHS diabetic eye screening; those details are not reproduced here.
  • The source notes the discontinuation of insulin detemir (Levemir) and states that NICE is assessing its impact on the insulin recommendations.
  • Licensing statements are time-specific. In the type 1 section, the source states that isCGM was licensed for children aged 4 years and over in March 2022. In the type 2 section, May 2023 notes describe isCGM use at age 3 years and under, non-standard-release metformin formulations and dulaglutide as off-licence or off-label.
  • This summary is selective. Education, dietary, exercise, psychosocial, surgery and service-provision recommendations are covered only partially or omitted. The lists of features suggesting type 2 diabetes and of features prompting suspicion of DKA in known diabetes are also partial.

This summary is selective and does not reproduce every recommendation. Apply the source’s population, setting and eligibility criteria, together with clinical judgement and local policy.

Summary sources

  1. 1
    Diabetes (type 1 and type 2) in children and young people: diagnosis and management

    Guideline recommendation text consulted

Original guideline

Publication details

Issuing organisation
NICE
First published
1 August 2015
Publisher’s latest update
11 May 2023
Resource type
Clinical guideline · House clinical summary

The source check confirms publication details and the linked edition. It does not certify every recommendation or its suitability for an individual patient. Publisher access conditions may apply.

On this page

  • Scope
  • Diagnosis and referral
  • Type 1 diabetes: treatment, targets and monitoring
  • Hypoglycaemia (type 1 diabetes)
  • Type 2 diabetes: treatment and monitoring
  • Diabetic ketoacidosis
  • Complication monitoring
  • Limitations and use
  • Summary sources
  • Publication details
House
Clinical AIRoundsGuidelinesCalculatorsPricingBlogAboutEditorial policyPrivacyTermsLog in ↗
Clinical intelligence, for physicians.© 2026 House